More information: Jaroslaw Dulski et al, Global Presence and Penetrance of CSF1R -Related Disorder, Neurology Genetics (2024) ...

The drug is an orally active inhibitor of CSF1R that, if approved, would compete with Daiichi Sankyo’s Turalio (pexidartinib), a CSF1R, KIT, and FLT3 inhibitor that was cleared for TGCT by the ...